Myriad's Q2 Miss and Guidance Cut Crush Stock; Fraud Probe Adds Risk
Q2 revenue miss and guidance cut Myriad's Q2 revenue fell 11% to $190.7M, missing estimates, and the company slashed full-year revenue guidance by over 10% to $770–790M. This signals weakening demand and pricing, pushing the stock down sharply.
This is the core negative event that drove the stock down 46% and is new this period.
Securities fraud investigation Kirby McInerney LLP is investigating Myriad for potential securities fraud related to its Q2 results and guidance cut. This adds legal uncertainty and could lead to further financial penalties, weighing on the stock.
This is a new development that increases risk and could pressure the stock further.
Precise MRD test expansion Myriad expanded its Precise MRD test to breast, colorectal, and renal cancers, backed by positive study results. This opens a larger market and could drive future revenue growth, but the impact is longer-term.
This is a new positive development that could support future growth, though it was overshadowed by negative financials.